Having established a role of SMARCE1 in regulating metastatic potential of breast cancer cells through the HIF1A/PTK2 pathway, we sought to examine the clinical relevance of this finding by examining the relationship between the SMARCE1 and PTK2 expression and the clinical outcomes of breast cancer patients. Here, HIF1A is linked to breast carcinoma.